When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AIMT - Aimmune's Palforzia shows durable effect in study
Aimmune Therapeutics Inc.
Aimmune Therapeutics (AIMT+3.6%) announces positive data from a follow-on study to its Phase 3 PALISADE trial of peanut allergy product Palforzia [peanut (Arachis hypogaea) allergen powder-dnfp].
More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Stocks on the move,